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Designing Better, Not Just Bigger, Multicenter Critical Care Trials
To the Editor:
I n a recent article in Critical Care Medicine, Landoni et al (1) report their assessment of multicenter trials that have reported mortality effects in adult critically ill patients and make suggestions, to which we respond as follows.
First, they argue that future trials should enroll more patients. Certainly, underpowered trials are too common and problematic (2) , and there are indeed merits to large and simple trials. Yet the costs and tradeoffs of pursuing bigger trials in terms of delay in results, expense, and temporal change that can influence results are large. Although not offered as a recommendation, there is also considerable opportunity for innovation in critical care medicine using adaptive trial designs, especially when examining limitedly understood interventions (2, 3) . One promising design is a seamless phase II/III trial that begins with several treatment arms and then, based on observed patient outcomes during the progress of the trial, algorithmically prunes inferior or harmful arms (e.g., doses of drug) and proceeds directly into phase III with the promising arm(s) retained (3). These adaptive designs can be completed years before separate phase II and III trials. Furthermore, they will enroll considerably fewer patients at a lower cost and terminate faster in situations of null or harmful effects.
Second, the authors promote a greater number of participating trial centers (1) . Although the multicenter design increases the likelihood of attaining adequate sample sizes, the diverse characteristics that vary across ICUs, such as intensivist practice patterns, protocols, or the acumen of trainees and staff, can exert a powerful influence on patient outcomes. As the goal is to decrease the mortality of a broadly defined syndrome (e.g., sepsis or acute respiratory distress syndrome), the resultant patient population in multicenter trials comprises an admixture of heterogeneous patients across a range of acuity, treated diversely across centers and providers. Because of such great patient heterogeneity, mortality should be adjusted, at a minimum, for patient acuity and center effects. This is especially important when the contribution of enrolled patients differs across centers, and failure to do so can lead to complex and unpredictable type I or II errors when comparing trial arms (4) (5) (6) .
Finally, we suggest that some often-missing specific data are needed at the patient and provider levels such as information on patient and physician preferences to use life-sustaining therapy because those preferences can affect time of and rates of death in the critically ill (7) .
To assume that only an intervention can impact mortality in a trial gives too much credence to the power of randomization. Deeper understanding of all trials is essential to assess any evidence base.
Multicenter trials are paramount to examine the external validity and generalizability of intervention(s). Before making our trials bigger, we argue that there is considerable opportunity to first better leverage novel trial designs, trial data, and empirical tools during analysis that could provide increased insight into the observed results while optimizing finite patient, time, and financial resources.
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W e thank Drs. Harhay and Russell for their insightful comments (1) . We agree that innovation in trial design is crucial to improving the quality, robustness, clinical plausibility, and global acceptability of the evidence behind the practice of intensive care medicine and have previously argued in favor of such innovation (2) (3) (4) (5) . Furthermore, we have extensively supported the need for greater rigor by means of presubmission publication of protocols and statistical analysis plans (6) (7) (8) (9) (10) (11) (12) . We also appreciate the importance of adaptive trial designs. We note, however, that they have not yet delivered new major findings to guide safe and effective practice in our field. In contrast, several large traditional design studies have already done so (13-15). Nonetheless, we look forward to their arrival on to the critical care scene.
We also appreciate the impact of patient heterogeneity and the importance of center-stratified and illness severity-stratified randomization in minimizing the impact of such heterogeneity on outcomes. However, we respectfully suggest that interventions that are only applied to a very select subgroup of patients will have difficulty in recruiting a sufficient number of patients to achieve adequate power over a reasonable time period. Furthermore, the application of their findings to clinical practice will likely deviate back to more heterogeneous populations because clinicians typically do not apply the same trial-based stringent selection criteria to their patient selection.
Finally, we acknowledge that different clinicians have different views of end-of-life care, which can impact mortality times and rates. However, we contend that such issues can be dealt with by increasing trial size, center number, using doubleblinding, and applying robust outcomes, which are remote in time form treatment allocation.
For those who are concerned about the cost of trials, we wish to passionately argue that the daily application of random preference-based medicine instead of the testing of interventions through randomized medicine for the treatment of critically ill patients has much, much greater cost to patients and the community and represents a serious threat to our ability to progressively, step by step, define best care in this vulnerable cohort.
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